Inovio » About Us » Leadership » Biography

"Vaccines are among the greatest achievements of biomedical science and public health, stimulating protective immune responses against acute and chronic infectious diseases, as well as some infectious diseases that result in cancer."

Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
Journal of the American Medical Association
November, 2007

"I have stated in public seminars that, in my opinion, electroporation is the gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines."

George N. Pavlakis, MD, PhD
Chief
Human Retrovirus Section, Vaccine Branch
National Cancer Institute

home » about us » leadership » david b. weiner, ph.d.

Biography

David B. Weiner, Ph.D.
Chairman, Scientific Advisory Board, Inovio Pharmaceuticals
Professor, Dept. of Pathology & Laboratory Medicine, University of Pennsylvania

DAVID WEINER is a world-renowned leader in immunology as well as gene vaccines and therapy. As a pioneer in the field of DNA vaccines, he has over 300 peer-reviewed publications in scientific journals to his credit and publication in mainstream scientific journals such as Scientific American. Dr. Weiner has been selected by the Institute for Scientific Information as one of the top cited scientists in the world. He was also the editor of several published books. Dr. Weiner's many credits attest to his pivotal role in developing gene-based vaccines and therapies. Dr. Weiner serves and has served as an advisor to and collaborator with leading companies such as American Home Products, 3M, J&J, GSK, Mobil and Centocor. Dr. Weiner played a key role in the start-up of biotechnology companies such as Apollon (one of the world's first DNA vaccines companies), Synbiotics, Immune Pharmaceutics, Verigen, and Symphony Pharmaceutics. He is a special employee and advisor for FDA/CBER and the NIH-NIAID-DAIDS Grant Review process. Dr. Weiner was a co-founder of VGX Pharmaceuticals, which merged with Inovio Pharmaceuticals in June 2009.